Tempest Therapeutics Inc
$ 1.79
-0.56%
24 Apr - close price
- Market Cap 25,675,800 USD
- Current Price $ 1.79
- High / Low $ 1.88 / 1.77
- Stock P/E N/A
- Book Value 1.35
- EPS -6.33
- Next Earning Report 2026-05-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.57 %
- ROE -2.04 %
- 52 Week High 12.23
- 52 Week Low 1.50
About
Tempest Therapeutics Inc., a clinical-stage oncology company, is dedicated to the development of small molecules that combine targeted and immune-mediated mechanisms with the potential to treat various tumors. The company is headquartered in South San Francisco, California.
Analyst Target Price
$10.50
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-30 | 2025-11-05 | 2025-08-11 | 2025-05-07 | 2025-03-17 | 2024-11-06 | 2024-08-08 | 2024-05-09 | 2024-03-19 | 2023-11-08 | 2023-08-10 | 2023-05-10 |
| Reported EPS | -0.62 | -0.79 | -2.07 | -3.16 | -0.31 | -0.41 | -0.42 | -0.36 | -0.38 | -0.48 | -0.54 | -0.55 |
| Estimated EPS | -0.62 | -0.2917 | -0.28 | -3.2933 | -0.245 | -0.36 | -0.4 | -0.37 | -0.39 | -0.57 | -0.52 | -0.64 |
| Surprise | 0 | -0.4983 | -1.79 | 0.1333 | -0.065 | -0.05 | -0.02 | 0.01 | 0.01 | 0.09 | -0.02 | 0.09 |
| Surprise Percentage | 0% | -170.8262% | -639.2857% | 4.0476% | -26.5306% | -13.8889% | -5% | 2.7027% | 2.5641% | 15.7895% | -3.8462% | 14.0625% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-12 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.28 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TPST
2026-04-24 23:09:54
Tempest Therapeutics' stock (TPST) crashed following its announcement to acquire two preclinical CAR-T programs from a privately held biotechnology company in an all-stock transaction. The deal, which includes a leading program for relapsed/refractory multiple myeloma, could be worth up to $225 million in milestone payments. This news overshadowed the positive clinical update on TPST-1120 for cholangiocarcinoma.
2026-04-22 13:39:39
Tempest Therapeutics has achieved a key manufacturing milestone for its dual-targeting CAR-T therapy, TPST-2003, with the delivery of the lentiviral vector to Cincinnati Children’s Applied Gene and Cell Therapy Center. This advancement is crucial for initiating a potentially registrational study in Q4 2026 for relapsed/refractory multiple myeloma patients. The milestone follows positive interim data from the REDEEM-1 Phase 1/2a trial, which showed a 100% complete response rate in all six efficacy evaluable patients.
2026-04-22 12:09:38
Tempest Therapeutics has achieved a key manufacturing milestone for its dual-targeting CD19/BCMA CAR-T therapy, TPST-2003, with the delivery of the lentiviral vector to its manufacturing partner, Cincinnati Children’s Applied Gene and Cell Therapy Center. This step is crucial for initiating a registrational study for TPST-2003 later this year, particularly for patients with relapsed/refractory multiple myeloma. The milestone follows positive interim data from the REDEEM-1 Phase 1/2a trial, which showed a 100% complete response rate in all six efficacy evaluable patients.
2026-04-14 23:11:11
Tempest Therapeutics has appointed Andrew Fang, Ph.D., as Head of Business Development to lead global business development efforts, focusing on strategic partnerships and expanding outreach in China. This move aims to advance potential partnerships for its Phase 3-ready amezalpat program and strengthen collaborations across its CAR-T portfolio. Dr. Fang brings extensive experience in cross-border licensing and biotech financing, particularly between the U.S. and Chinese biotech ecosystems.
2026-04-14 14:20:00
Tempest Therapeutics has appointed Andrew Fang, Ph.D., as Head of Business Development to spearhead global partnerships and expand the company's presence in China. Fang's expertise in cross-border licensing and strategic transactions is crucial as Tempest seeks partners for its Phase 3-ready hepatocellular carcinoma program, amezalpat. This appointment aligns with Tempest's recent strategic pivot into CAR-T therapy, which has been well-received by analysts, including an upgrade to "Buy" from H.C. Wainwright.
2026-04-14 13:10:59
Tempest Therapeutics has appointed Andrew Fang, Ph.D., as its new Head of Business Development to lead global partnerships and China outreach efforts. Dr. Fang will focus on strategic transactions, cross-border licensing, and expanding the company's presence in China, particularly for its Phase 3-ready amezalpat program. The appointment follows recent significant developments for Tempest, including a private placement, promising clinical data for its CAR-T therapy, and the acquisition of new CAR-T assets, leading to an analyst upgrade to 'Buy'.
